Pfizer's Berobenatide GLP-1 injection shows efficacy in obesity and diabetes in early data

Pfizer presented early data on its long-acting GLP-1 injection, Berobenatide, at a conference on June 6, 2026.

The results indicated the drug was effective in patients who have both obesity and diabetes, according to the presented data.

Berobenatide was the centerpiece of Pfizer’s acquisition of Metsera last year, and its performance could shape pricing and dosing strategies in a crowded GLP-1 market.